Free Trial

Lyra Therapeutics (LYRA) Competitors

Lyra Therapeutics logo
$0.20 -0.01 (-4.08%)
Closing price 04:00 PM Eastern
Extended Trading
$0.20 +0.00 (+1.82%)
As of 05:22 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

LYRA vs. INO, MODD, NXL, MBOT, BLAC, OM, CLGN, BDMD, MDAI, and NMTC

Should you be buying Lyra Therapeutics stock or one of its competitors? The main competitors of Lyra Therapeutics include Inovio Pharmaceuticals (INO), Modular Medical (MODD), Nexalin Technology (NXL), Microbot Medical (MBOT), Bellevue Life Sciences Acquisition (BLAC), Outset Medical (OM), CollPlant Biotechnologies (CLGN), Baird Medical Investment (BDMD), Spectral AI (MDAI), and NeuroOne Medical Technologies (NMTC). These companies are all part of the "medical equipment" industry.

Lyra Therapeutics vs.

Inovio Pharmaceuticals (NASDAQ:INO) and Lyra Therapeutics (NASDAQ:LYRA) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, media sentiment, earnings, profitability, valuation, community ranking, analyst recommendations, institutional ownership and risk.

In the previous week, Inovio Pharmaceuticals had 3 more articles in the media than Lyra Therapeutics. MarketBeat recorded 3 mentions for Inovio Pharmaceuticals and 0 mentions for Lyra Therapeutics. Inovio Pharmaceuticals' average media sentiment score of 0.36 beat Lyra Therapeutics' score of 0.00 indicating that Inovio Pharmaceuticals is being referred to more favorably in the media.

Company Overall Sentiment
Inovio Pharmaceuticals Neutral
Lyra Therapeutics Neutral

Inovio Pharmaceuticals received 696 more outperform votes than Lyra Therapeutics when rated by MarketBeat users. Likewise, 71.15% of users gave Inovio Pharmaceuticals an outperform vote while only 60.00% of users gave Lyra Therapeutics an outperform vote.

CompanyUnderperformOutperform
Inovio PharmaceuticalsOutperform Votes
720
71.15%
Underperform Votes
292
28.85%
Lyra TherapeuticsOutperform Votes
24
60.00%
Underperform Votes
16
40.00%

Inovio Pharmaceuticals has a net margin of 0.00% compared to Lyra Therapeutics' net margin of -6,635.76%. Inovio Pharmaceuticals' return on equity of -118.17% beat Lyra Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Inovio PharmaceuticalsN/A -118.17% -83.47%
Lyra Therapeutics -6,635.76%-125.07%-59.74%

26.8% of Inovio Pharmaceuticals shares are held by institutional investors. Comparatively, 95.6% of Lyra Therapeutics shares are held by institutional investors. 2.5% of Inovio Pharmaceuticals shares are held by company insiders. Comparatively, 4.7% of Lyra Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Lyra Therapeutics has higher revenue and earnings than Inovio Pharmaceuticals.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Inovio Pharmaceuticals$830K66.67-$135.12MN/AN/A
Lyra Therapeutics$1.56M8.39-$62.68M-$1.49-0.13

Inovio Pharmaceuticals has a beta of 0.89, indicating that its stock price is 11% less volatile than the S&P 500. Comparatively, Lyra Therapeutics has a beta of -0.14, indicating that its stock price is 114% less volatile than the S&P 500.

Inovio Pharmaceuticals presently has a consensus price target of $12.40, suggesting a potential upside of 484.91%. Lyra Therapeutics has a consensus price target of $4.50, suggesting a potential upside of 2,150.00%. Given Lyra Therapeutics' higher probable upside, analysts plainly believe Lyra Therapeutics is more favorable than Inovio Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Inovio Pharmaceuticals
0 Sell rating(s)
2 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.60
Lyra Therapeutics
1 Sell rating(s)
4 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Summary

Inovio Pharmaceuticals beats Lyra Therapeutics on 10 of the 16 factors compared between the two stocks.

Get Lyra Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for LYRA and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

LYRA vs. The Competition

MetricLyra TherapeuticsSurgical & medical instruments IndustryMedical SectorNASDAQ Exchange
Market Cap$13.09M$4.68B$5.80B$9.18B
Dividend YieldN/A50.78%5.25%3.99%
P/E Ratio-0.1324.1424.6319.28
Price / Sales8.3962.70468.8379.21
Price / CashN/A50.9644.6537.93
Price / Book0.136.807.645.18
Net Income-$62.68M$90.91M$3.19B$245.95M
7 Day Performance1.78%2.03%1.13%1.88%
1 Month Performance4.93%1.56%3.14%1.34%
1 Year Performance-96.02%17.39%20.18%16.07%

Lyra Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
LYRA
Lyra Therapeutics
2.3808 of 5 stars
$0.20
-4.1%
$4.50
+2,179.6%
-95.9%$12.92M$1.56M-0.1350
INO
Inovio Pharmaceuticals
3.6234 of 5 stars
$1.92
-2.3%
$12.40
+547.5%
-72.4%$49.98M$830,000.000.00320
MODD
Modular Medical
2.8351 of 5 stars
$1.22
+0.4%
$5.00
+311.5%
-36.9%$49.21MN/A-1.9220Earnings Report
Negative News
NXL
Nexalin Technology
1.063 of 5 stars
$3.53
-5.2%
$3.00
-14.9%
+917.3%$46.88M$110,000.00-5.513News Coverage
MBOT
Microbot Medical
2.1896 of 5 stars
$2.31
-9.6%
$9.00
+290.5%
+48.8%$46.65MN/A-2.8820Gap Down
High Trading Volume
BLAC
Bellevue Life Sciences Acquisition
N/A$10.93
-2.6%
N/A-73.7%$44.15MN/A0.00N/AGap Down
OM
Outset Medical
2.1555 of 5 stars
$0.78
-3.5%
$4.50
+475.4%
-73.4%$41.62M$130.38M-0.28520Earnings Report
News Coverage
Gap Down
CLGN
CollPlant Biotechnologies
2.2875 of 5 stars
$3.61
-1.4%
$12.50
+246.3%
-34.4%$41.28M$10.96M-2.3470High Trading Volume
BDMD
Baird Medical Investment
N/A$6.21
+5.3%
N/AN/A$40.86MN/A0.00N/A
MDAI
Spectral AI
2.6153 of 5 stars
$2.20
+6.9%
$4.75
+115.7%
+2.6%$40.81M$18.06M-3.3883News Coverage
Gap Up
NMTC
NeuroOne Medical Technologies
0.2693 of 5 stars
$1.22
+14.0%
N/A+12.6%$38.27M$3.45M-2.7020Earnings Report

Related Companies and Tools


This page (NASDAQ:LYRA) was last updated on 2/19/2025 by MarketBeat.com Staff
From Our Partners